Added to YB: 2024-04-30
Pitch date: 2024-03-31
RNA [bullish]
Avidity Biosciences, Inc.
+179.6%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Market Cap
$10.8B
Pitch Price
$25.69
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.84
P/E
-17.12
EV/Sales
429.70
Sector
Biotechnology
Category
growth
Show full summary:
Artisan International Small-Mid Fund Portfolio Holding: Avidity Biosciences, Inc.
Avidity's AOC platform combines antibodies & siRNA for rare diseases like DM1. Phase 2 data validated platform safety/efficacy. Phase 3 to start in Q2 with strong pipeline potential beyond muscle diseases. Diligence suggests earlier adverse event was isolated.
Read full article (1 min)